ID   MRCC
AC   CVCL_U325
SY   HiMet-ccRCC
DR   CCRID; 4201PAT-CCTCC00277
DR   Wikidata; Q54906732
RX   Patent=CN101508972A;
RX   PubMed=23442546;
RX   PubMed=27993170;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200909.
CC   Population: Chinese.
CC   Doubling time: 55.2 hours (PubMed=23442546).
CC   Derived from site: Metastatic; Bone, spine; UBERON=UBERON_0001130.
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 29-06-23; Version: 14
//
RX   Patent=CN101508972A;
RA   Chang W.-J., Cao G.-W., Lin L.-P., Tan X.-J., He S.-Q.;
RT   "High-transfer kidney clear cell cancer cell system for the Han
RT   nationality.";
RL   Patent number CN101508972A, 19-Aug-2009.
//
RX   PubMed=23442546; DOI=10.1186/1475-2867-13-20;
RA   Tan X.-J., He S.-Q., Han Y.-F., Yu Y.-W., Xiao J.-R., Xu D.-F.,
RA   Wang G.-P., Du Y., Chang W.-J., Yin J.-H., Su T., Hou J.-G., Cao G.-W.;
RT   "Establishment and characterization of clear cell renal cell carcinoma
RT   cell lines with different metastatic potential from Chinese
RT   patients.";
RL   Cancer Cell Int. 13:20.1-20.11(2013).
//
RX   PubMed=27993170; DOI=10.1186/s12943-016-0565-8;
RA   Brodaczewska K.K., Szczylik C., Fiedorowicz M., Porta C.,
RA   Czarnecka A.M.;
RT   "Choosing the right cell line for renal cell cancer research.";
RL   Mol. Cancer 15:83.1-83.15(2016).
//